Basic Information
-
Work Experience and Professional Background
I, Yu Junli, a Chinese national without permanent residency abroad, male, born in June 1983, hold a Ph.D. in Accounting and a postdoctoral degree in Business Administration. I am an associate professor and master's and doctoral supervisor at Shanghai Jiao Tong University, and a researcher at Antai College of Economics and Management. I serve as the deputy editor of SN Social Science and a member of the editorial board of Urban Governance. I am also a review expert for the National Natural Science Foundation, Shanghai Finance Bureau, and Shanghai Public Resources Platform, and have been recognized as a Morning Light Scholar in Shanghai. Currently, I also serve as an independent director for Zhejiang Dibai Electric Co., Ltd. and Shandong WoHua Pharmaceutical Technology Co., Ltd. I obtained the independent director qualification certificate and have served as an independent director of the company since May 2024. -
Independence Status
During my tenure as an independent director, I have not held any position other than independent director in the company, nor have I held any position in the major shareholder's company. There are no relationships with the company or major shareholders that could hinder my independent and objective judgment, and I meet the independence requirements outlined in relevant laws and regulations.
Performance in 2025
In 2025, I attended the board and shareholder meetings convened by the company, actively understanding the company's operational status and communicating with relevant personnel to verify important matters. I carefully listened to and reviewed each proposal during meetings, participated in discussions, and provided reasonable suggestions, exercising my voting rights with a rigorous attitude to contribute to scientific decision-making for the company. After meetings, I continued to monitor the implementation of proposals.
-
Attendance at Board and Shareholder Meetings
(1) The meetings of the board and shareholders in 2025 were convened in accordance with legal procedures, and major operational decisions and other significant matters were carried out according to relevant regulations, with resolutions being legal and effective.
(2) In 2025, the company held 7 board meetings; I personally attended all meetings I was required to attend and voted in favor of all relevant proposals.
(3) In 2025, Hubei Hendi Pharmaceutical Co., Ltd. held three shareholder meetings, all of which I personally attended. -
Independent Director Special Meetings
No special meetings of independent directors were held during the reporting period. -
Performance in Board Committees
Name Required Attendance Actual Attendance Proxy Attendance Absences Consecutive Absences Yu Junli 7 7 0 0 No